BioNTech: Marburg manufacturing site
BioNTech Marburg Manufacturing GmbH
BioNTech Marburg Manufacturing GmbH
In this substack I will focus on the BioNTech Marburg manufacturing site because the history of the site seems to be important for the course of the manufacturing of the mRNA-Injections provided globally by BioNTech and Pfizer during the p(l)andemic years from 2020 to 2023.
Whether or not manufacturing was really done here in Marburg needs to be clarified asap. My gut feeling is that the only manufacturing site was the Pfizer site in Puurs, Belgium. This site was visited by Pfizer CEO Albert Bourla and Ursula von der Leyen on April 23, 2021.
Marburg
Marburg has a long and tangled history with viruses and vaccines. Therefore I will cover this in several substacks but most importantly is the following timeline of ownership.
Novartis
Pharmaserv GmbH
BioNTech
Infrareal
Swiss Life Asset Managers
BioNTech Marburg
BioNTech buys Novartis plant for COVID-19 vaccine, eyes capacity of up to 750M doses
BioNTech and its partner Pfizer have multiple COVID-19 vaccine supply deals in the bag, and a major production expansion is due.
BioNTech has agreed to buy a biologics facility in its home country from Novartis, the German biotech said Thursday. Expected to be fully operational in the first half of 2021, the Marburg site could have annual capacity of up to 750 million doses of the company’s experimental mRNA shot, BNT162.
As Novartis has already invested more than $109 million in the site since settling in there in 2015, BioNTech expects a quick turnaround once the transaction closes by year’s end. It plans to produce up to 250 million doses of BNT162b2, currently the lead candidate among five in the BNT162 program, in the first half of 2021.
BioNTech buys Novartis plant for COVID-19 vaccine, eyes capacity of up to 750M doses
BioNTech Acquiring Novartis’ Marburg Site
September 2020 - German biotech BioNTech has signed a share purchase agreement with Novartis to acquire the Swiss drugmaker’s GMP-certified manufacturing facility in Marburg, Germany. The deal will expand the Mainz-based company’s Covid-19 vaccine production capability by up to 750 million doses per year, or over 60 million doses per month, when fully operational.
BioNTech Acquiring Novartis’ Marburg Site
Novartis Marburg
Pharmaserv
Pharmaserv Logistics, the logistics brand of Pharmaserv GmbH, can look back on a past that is steeped in tradition. As site operators and owners of the Behringwerke pharma and biotech park, Pharmaserv and its infrastructure services ensure that blood products and vaccines are still successfully manufactured in Marburg today.
Link to Pharamserv website with history:
More than 100 years of experience with biologics
Pharmaserv
Swiss Life Asset Managers
On July 27, 2021
Swiss Life Asset Managers, on behalf of a Swiss Life Infrastructure Fund, and Gelsenwasser AG have agreed to acquire Infrareal GmbH, an owner and operator of Behringwerke and Jena life science parks.
Infrareal
Baker McKenzie
Baker McKenzie advised the shareholders of Infrareal GmbH on the sale of all shares in the company to Swiss Life Asset Managers and Gelsenwasser. Infrareal is the owner and operator of two prime life science-focused industrial parks in Marburg and Jena, Germany and helps its clients focus on their core manufacturing and R&D competencies.
As with the management buy-out more than 16 years ago, in which the shareholders had acquired the shares from Sanofi at the time, Baker McKenzie again advised the shareholders on all legal aspects of the transaction with a team lead by Dr. Thomas Gilles.
Swiss Life Asset Managers is one of Europe's leading infrastructure asset managers, with EUR 5.8 billion in infrastructure assets alone.
Gelsenwasser AG is a listed German infrastructure and utility company. In addition to water, gas and electricity supply and wastewater disposal, its areas of activity also include services for infrastructure, renewable energies, digital grids and neighborhood concepts.
to be updated … please stay tuned